Lithium treatment attenuates muscarinic M1 receptor dysfunction

Bipolar Disorders

Volumn 13, Issue 3, 2011, Pages 238-249

  Creson, Thomas K ^a   Austin, Daniel R ^a   Shaltiel, Galit ^a   Mccammon, Joseph ^a   Wess, Jürgen ^b   Manji, Husseini K ^a   Chen, Guang ^a,c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c LLC   (United States)

Author keywords

ERK; GSK 3; Lithium; M1; Mania; MiRNA

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; LITHIUM CARBONATE; MARCKS PROTEIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUSCARINIC M1 RECEPTOR; NEUROMODULIN; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FRONTAL CORTEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RNA TRANSLATION; SIGNAL TRANSDUCTION;

AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIMANIC AGENTS; CELLS, CULTURED; CEREBRAL CORTEX; DRUG INTERACTIONS; EXPLORATORY BEHAVIOR; FRONTAL LOBE; GAP-43 PROTEIN; GENE EXPRESSION REGULATION; HYPERKINESIS; INTERPERSONAL RELATIONS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LITHIUM; MAZE LEARNING; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEURONS; RATS; RATS, INBRED WKY; RECEPTOR, MUSCARINIC M1; SWIMMING;

EID: 79959205954     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2011.00915.x     Document Type: Article

References (48)

1. Wess J. Molecular biology of muscarinic acetylcholine receptors. Crit Rev Neurobiol 1996; 10: 69-99.
2. Wess J. Physiological roles of G-protein-coupled receptor kinases revealed by gene-targeting technology. Trends Pharmacol Sci 2000; 21: 364-367.
3. Nathanson NM. Molecular properties of the muscarinic acetylcholine receptor. Annu Rev Neurosci 1987; 10: 195-236.
4. + channel activity in sympathetic neurons. Life Sci 2001; 68: 2481-2487.
5. Jimenez E, Montiel M. Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells. J Cell Physiol 2005; 204: 678-686.
6. Montiel M, Quesada J, Jimenez E. Activation of calcium-dependent kinases and epidermal growth factor receptor regulate muscarinic acetylcholine receptor-mediated MAPK/ERK activation in thyroid epithelial cells. Cell Signal 2007; 19: 2138-2146.
7. Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. 2nd ed. New York: Oxford University Press, 2007.
8. Jope RS, Song L, Li PP et al. The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain. J Neurochem 1996; 66: 2402-2409.
9. Cannon DM, Carson RE, Nugent AC et al. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry 2006; 63: 741-747.
10. Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 2006; 63: 1121-1129.
11. Drevets WC, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry 2010; 67: 432-438.
12. Berridge MJ, Irvine RF. Inositol phosphates and cell signalling. Nature 1989; 341: 197-205.
13. Farias GG, Godoy JA, Hernandez F, Avila J, Fisher A, Inestrosa NC. M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity. A role for Wnt signaling pathway. Neurobiol Dis 2004; 17: 337-348.
14. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459.
15. Gould TD, Chen G, Manji HK. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 2004; 29: 32-38.
16. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000; 48: 740-754.
17. Prickaerts J, Moechars D, Cryns K et al. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci 2006; 26: 9022-9029.
18. Engel SR, Creson TK, Hao Y et al. The extracellular signal-regulated kinase pathway contributes to the control of behavioral excitement. Mol Psychiatry 2009; 14: 448-461.
19. Zhou R, Yuan P, Wang Y et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 2009; 34: 1395-1405.
20. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 2007; 17: 118-126.
21. Hamilton SE, Loose MD, Qi M et al. Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. Proc Natl Acad Sci USA 1997; 94: 13311-13316.
22. Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 2007; 6: 721-733.
23. Anagnostaras SG, Murphy GG, Hamilton SE et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003; 6: 51-58.
24. Miyakawa T, Yamada M, Duttaroy A, Wess J. Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J Neurosci 2001; 21: 5239-5250.
25. Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S. Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci USA 2001; 98: 15312-15317.
26. Hao Y, Creson T, Zhang L et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci 2004; 24: 6590-6599.
27. Shaltiel G, Maeng S, Malkesman O et al. Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol Psychiatry 2008; 13: 858-872.
28. Zhou R, Gray NA, Yuan P et al. The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci 2005; 25: 4493-4502.
29. Einat H, Yuan P, Gould TD et al. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 2003; 23: 7311-7316.
30. Lad HV, Liu L, Paya-Cano JL et al. Behavioural battery testing: evaluation and behavioural outcomes in 8 inbred mouse strains. Physiol Behav 2010; 99: 301-316.
31. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002; 23: 238-245.
32. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 1999; 96: 8745-8750.
33. Porsolt RD, Brossard G, Hautbois C, Roux S. Rodent models of depression: forced swimming and tail suspension behavioral despair tests in rats and mice. Curr Protoc Neurosci 2001; 14:8.10A: 1-8.
34. Kocerha J, Faghihi MA, Lopez-Toledano MA et al. MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proc Natl Acad Sci USA 2009; 106: 3507-3512.
35. Hunsberger JG, Austin DR, Chen G, Manji HK. MicroRNAs in mental health: from biological underpinnings to potential therapies. Neuromolecular Med 2009; 11: 173-182.
36. Jones DR, Sanjuan MA, Stone JC, Merida I. Expression of a catalytically inactive form of diacylglycerol kinase alpha induces sustained signaling through RasGRP. FASEB J 2002; 16: 595-597.
37. Yuan P, Zhou R, Wang Y et al. Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. J Affect Disord 2010; 124: 164-169.
38. Chen G, Henter ID, Manji HK. Translational research in bipolar disorder: emerging insights from genetically based models. Mol Psychiatry 2010; 15: 883-895.
39. Roybal K, Theobold D, Graham A et al. Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci USA 2007; 104: 6406-6411.
40. Flaisher-Grinberg S, Einat H. A possible utilization of the mice forced-swim test for modeling manic-like increase in vigor and goal-directed behavior. J Pharmacol Toxicol Methods 2009; 59: 141-145.
41. Cryan JF, Valentino RJ, Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 2005; 29: 547-569.
42. David DJ, Renard CE, Jolliet P, Hascoet M, Bourin M. Antidepressant-like effects in various mice strains in the forced swimming test. Psychopharmacology 2003; 166: 373-382.
43. Lucki I, Dalvi A, Mayorga AJ. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 2001; 155: 315-322.
44. Gould TD, O'Donnell KC, Picchini AM, Manji HK. Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium. Neuropsychopharmacology 2007; 32: 1321-1333.
45. Tomasiewicz HC, Mague SD, Cohen BM, Carlezon WA Jr. Behavioral effects of short-term administration of lithium and valproic acid in rats. Brain Res 2006; 1093: 83-94.
46. Bersudsky Y, Shaldubina A, Belmaker RH. Lithium's effect in forced-swim test is blood level dependent but not dependent on weight loss. Behav Pharmacol 2007; 18: 77-80.
47. Ghasemi M, Sadeghipour H, Poorheidari G, Dehpour AR. A role for nitrergic system in the antidepressant-like effects of chronic lithium treatment in the mouse forced swimming test. Behav Brain Res 2009; 200: 76-82.
48. Lenox RH, McNamara RK, Watterson JM, Watson DG. Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? J Clin Psychiatry 1996; 57 (Suppl. 13): 23-31.